Epidemiology of Human Immunodeficiency Virus-Associated Pulmonary Disease

Clinics in Chest Medicine

Volumn 34, Issue 2, 2013, Pages 165-179

  Murray, John F ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (France)

Author keywords

Community acquired pneumonia; Human immunodeficiency virus; Pneumocystis pneumonia; Pulmonary disease; Tuberculosis

Indexed keywords

ANTIRETROVIRUS AGENT;

BACTERIAL PNEUMONIA; CHRONIC DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMMUNITY ACQUIRED PNEUMONIA; DEVELOPED COUNTRY; DEVELOPING COUNTRY; DISEASE ASSOCIATION; DRUG POTENCY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; LIFE EXPECTANCY; LUNG CANCER; LUNG COMPLICATION; LUNG DISEASE; LUNG INFECTION; LUNG TUBERCULOSIS; MULTIDRUG RESISTANT TUBERCULOSIS; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; COMMUNITY-ACQUIRED INFECTIONS; HIV INFECTIONS; HUMANS; LUNG DISEASES; MALE; PNEUMONIA, BACTERIAL; PNEUMONIA, PNEUMOCYSTIS; TUBERCULOSIS, PULMONARY;

EID: 84878141314     PISSN: 02725231     EISSN: 15578216     Source Type: Journal    
DOI: 10.1016/j.ccm.2013.02.004     Document Type: Review

References (76)

1. CDC Pneumocystis pneumonia-Los Angeles. MMWR Morb Mortal Wkly Rep 1981, 30:250-252.
2. CDC Kaposi's sarcoma and Pneumocystis pneumonia among homosexual men-New York City and California. MMWR Morb Mortal Wkly Rep 1981, 30:306-308.
3. Hymes K.B., Greene J.B., Marcus A. Kaposi's sarcoma in homosexual men: a report of 8 cases. Lancet 1981, 2:598-600.
4. Gottlieb M.S., Schnoff R., Schanker H.M., et al. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men- evidence of a new acquired cellular immunodeficiency. N Engl J Med 1981, 305:1425-1431.
5. Masur H., Michelis M.A., Greene J.B., et al. An outbreak of community-acquired Pneumocystis carinii pneumonia-initial manifestation of cellular immune dysfunction. N Engl J Med 1981, 305:1431-1438.
6. Siegal F.P., Lopez C., Hammer G.S., et al. Severe immune deficiency in male homosexuals, manifested by chronic perianal ulcerative Herpes simplex lesions. N Engl J Med 1981, 305:1439-1444.
7. Durack D.T. Opportunistic infections and Kaposi's sarcoma in homosexual men. N Engl J Med 1981, 305:1465-1467.
8. Barre-Sinoussi F., Chermann J.-C., Ray F., et al. Lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983, 220(4599):868-871.
9. Popovic M., Sangadharan M.G., Read E., et al. Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science 1984, 224(4648):497-500.
10. Bureau of Hygiene & Tropical Diseases. AIDS Newsletter 1986, 2(2).
11. Mann J.M. A worldwide pandemic. Current topics in AIDS 1989, vol. 2. John Wiley, Chichester (United Kingdom).
12. Murray J.F., Felton C.P., Garay S.M., et al. Pulmonary complications of the acquired immunodeficiency syndrome. Report of a National Heart, Lung, and Blood Institute Workshop. N Engl J Med 1984, 310:1682-1688.
13. Murray J.F., Garay S.M., Hopewell P.C., et al. NHLBI workshop summary. Pulmonary complications of the acquired immunodeficiency syndrome: an update. Report of the 2nd NHLBI workshop. Am Rev Respir Dis 1987, 135:504-509.
14. CDC Epidemiology of HIV/AIDS-United States, 1981-2005. MMWR Morb Mortal Wkly Rep 2006, 55:589-592.
15. Benitio N., Moreno A., Miro J.M., et al. Pulmonary infections in HIV-infected patients: an update in the 21st century. Eur Respir J 2012, 39:730-745.
16. Kaplan J.E., Benson C., Holmes K.K., et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents. Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009, 58:1-207.
17. Pitchenik A.E., Cole C., Russell R.W., et al. Tuberculosis, atypical myobacteriosis, and the acquired immunodeficiency syndrome among Haitian and non-Haitian patients in south Florida. Ann Intern Med 1984, 101:641-645.
18. The National Institutes of Health-University of California Expert Panel for Corticosteroids as Adjunctive Therapy for Pneumocystis Pneumonia. Consensus statement on the use of corticosteroids as adjunctive therapy for Pneumocystis pneumonia in the acquired immunodeficiency syndrome. N Engl J Med 1990, 323:1500-1504.
19. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008, 372:293-299. The Antiretroviral Therapy/Cohort Collaboration.
20. CDC Vital signs: HIV prevention through care and treatment - United States. MMWR Morb Mortal Wkly Rep 2011, 60:1618-1623.
21. Mann J., Snider D.F., Francis H., et al. Association between HTLV-III/LAV infection and tuberculosis in Zaire. JAMA 1986, 256:346.
22. Colebunders R.L., Ryder R.W., Nzliambi N., et al. HIV infection in patients with tuberculosis in Kinshasa, Zaire. Am Rev Respir Dis 1989, 139:1082-1085.
23. Harries A.D. Tuberculosis and human immunodeficiency virus infection in developing countries. Lancet 1990, 335(8686):387-390.
24. Murray J.F. Tuberculosis and human immunodeficiency virus infection during the 1990s. Bull Int Union Tuberc Lung Dis 1991, 86:21-25.
25. Lucas S.B., Hounnou A., Peacock C., et al. The mortality and pathology of HIV infection in a West African city. AIDS 1993, 7:1569-1579.
26. Kamanfu G., Mlika-Cabanne N., Girard P.M., et al. Pulmonary complications of human immunodeficiency virus infection in Bujumbura, Burundi. Am Rev Respir Dis 1993, 147:658-663.
27. Daley C.L., Mugusi F., Chen L.L., et al. Pulmonary complications of HIV infection in Dar Es Salaam, Tanzania. Role of bronchoscopy and bronchoalveolar lavage. Am J Respir Crit Care Med 1996, 154:105-110.
28. WHO Global tuberculosis control report 2011, Chapter 6, World Health Organization, Available at:, Accessed October 1, 2012. http://www.who.int/tb/publications/global_report/en/.
29. Anglaret X., Chene G., Attia A., et al. Early chemoprophylaxis with trimethoprim-sulfamethoxazole for HIV-1 infected adults in Abidjan, Cote d'Ivoire: a randomized trial. Cotrimo-CI Study Group. Lancet 1999, 353(9163):1463-1468.
30. Wiktor S.Z., Sassan-Morokro M., Grant A.D., et al. Efficacy of trimethoprim-sulfamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Cote d'Ivoire: a randomized controlled trial. Lancet 1999, 353(9163):1469-1475.
31. WHO Expert Consultation of Cotrimoxazole Prophylaxis in HIV Infection: report of a WHO expert consultation, Geneva, 10-12 May 2005 2006, World Health Organization, Geneva (Switzerland), Available at:, Accessed August 12, 2012. http://www.int/hiv/pub/meetingreports/ctxprophylaxismeeting.pdf.
32. CDC Reported tuberculosis in the United States, 2010 2011, US Department of Health and Human Services, CDC, Atlanta (GA), Available at:, Accessed August 12, 2012. http://www.cdc.gov/tb/statistics/reports/2010/default.htm.
33. Samandari T., Agizew T.B., Nyirenda S., et al. 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomized, double-blind, placebo-controlled trial. Lancet 2011, 377(9777):1588-1598.
34. Suthar A.B., Lawn S.D., del Amo J., et al. Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. PLoS Med 2012, 9(7):e1001270. 10.1371/journal.pmed.1001270.
35. Nakagawa F., Lodwick R.K., Smith C.J., et al. Projected life expectancy of people with HIV according to timing of diagnosis. AIDS 2012, 26:335-343.
36. Grant R.M., Larra J.R., Anderson P.L., et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010, 363:2587-2590.
37. Abdool Karim Q., Abdool Karim S.S., Frolich J.A., et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide for the prevention of HIV infection in women. Science 2010, 329:1168-1174.
38. Hefferman R.T., Garrett N.L., Gallagher K.M., et al. Declining incidence of invasive Streptococcus pneumoniae infections among persons with AIDS in an era of highly active antiretroviral therapy, 1995-2000. J Infect Dis 2005, 191:2038-2045.
39. Hirshtick R.E., Glassroth J., Jordan M.C., et al. Bacterial pneumonia in persons infected with the human immunodeficiency virus. N Engl J Med 1995, 333:845-851.
40. Castro K.G., Ward J.W., Aluraker L., et al. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992, 41(RR-17):1-19.
41. Hull M.W., Phillips P., Montaner J.S.G. Changing global epidemiology of pulmonary manifestations of HIV.AIDS. Chest 2008, 134:1287-1298.
42. Tumbarello M., Tacconelli E., de Gaetano Donati K., et al. Nosocomial bacterial pneumonia in human immunodeficiency virus infected subjects: incidence, risk factors and outcome. Eur Respir J 2001, 17:636-640.
43. Franzetti F., Grassini A., Piazza M., et al. Nosocomial bacterial pneumonia in HIV-infected patients: risk factors for adverse outcome and implications for rational empiric antibiotic therapy. Infection 2006, 34:9-16.
44. Bozzette S.A., Arcia J., Bartok A.E., et al. Impact of Pneumocystis carinii and cytomegalovirus on the course and outcome of atypical pneumonia in advanced human immunodeficiency virus disease. J Infect Dis 1992, 165:93-98.
45. CDC. Seasonal influenza (Flu) - HIV/AIDS and the flu. Available at: . Accessed August 15, 2012. http://www.cdc.gov/flu/protect/hiv-flu.htm.
46. Notifications of tuberculosis by type of disease, Tanzania, 1984-1999. Tanzania NTLP/IUATLD. Progress report 1996, No. 36; Tanzania NTLP/KNCV. Report 2000; No.7.
47. CDC. HIV and TB. Available at: . Accessed August 25, 2012. http://www.cdc.gov/hiv/resources/factsheet/hivtb.htm.
48. Chamie G., Luetkemeyer A., Walusimbi-Nanteza M., et al. Significant variation in presentation of pulmonary tuberculosis across a high resolution of CD4 strata. Int J Tuberc Lung Dis 2010, 14:1295-1302.
49. Corbett E.L., Charalambous T., Cheung Y.B., et al. Epidemiology of tuberculosis in a high HIV prevalence population provided with enhanced diagnosis of symptomatic disease. PLoS Med 2007, 4:e22.
50. Blanc F.X., Sok T., Laureillard D., et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med 2011, 365:1471-1481.
51. Havlir D.V., Kendall M.A., Ive P., et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med 2011, 365:1482-1491.
52. Abdool Karim S.S., Naidoo K., Grobler A., et al. Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med 2011, 365:1492-1501.
53. Torok M.E., Farrar J.J. When to start antiretroviral therapy in HIV-associated tuberculosis. N Engl J Med 2011, 365:1538-1540.
54. Torok M.E., Yee N.T., Chau T.T., et al. Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)-associated tuberculosis meningitis. Clin Infect Dis 2011, 52:1374-1383.
55. WHO WHO policy on collaborative TB/HIV activities. Guidelines for national programmes and other stakeholders 2012, WHO, Geneva (Switzerland), WHO/HIV/2012.1.
56. French M.A. Immune reconstitution inflammatory syndrome: a reappraisal. Clin Infect Dis 2009, 48:101-107.
57. Naidoo K., Yende-Zumz N., Padayatchi N., et al. The immune reconstitution inflammatory syndrome after antiretroviral therapy initiation in patients with tuberculosis: findings from the SAPiT Trial. Ann Intern Med 2012, 157:313-324.
58. WHO Tuberculosis control report. Executive Summary 2011, World Health Organization, Available at:, Accessed October 1, 2012. http://www.who.int/tb/publications/global_report/en/.
59. Zhao Y., Xu S., Wang L., et al. National survey of drug-resistant tuberculosis in China. N Engl J Med 2012, 366:2161-2170.
60. Gandhi N.R., Moll A., Sturm A.W., et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006, 368:1575-1580.
61. Gandhi N.R., Andrews J.R., Brust J.C., et al. Risk factors for mortality among MDR- and XDR-TB in a high HIV prevalence setting. Int J Tuberc Lung Dis 2012, 16:90-97.
62. Brust J.C., Shah N.S., Scott M., et al. Integrated, home-based treatment for MDR-TB and HIV in rural South Africa: an alternate model of care. Int J Tuberc Lung Dis 2012, 16:998-1004.
63. Nguyen H.Q., Magaret A.S., Kitahata M.M., et al. Persistent Kaposi sarcoma in the era of highly active antiretroviral therapy: characterizing the predictors of clinical response. AIDS 2008, 11:937-945.
64. Palmieri C., Dhillon T., Thirlwell C., et al. Pulmonary Kaposi sarcoma in the era of highly active antiretroviral therapy. HIV Med 2006, 7:291-293.
65. Lim S.T., Karim R., Tulpule A., et al. Prognostic factors in HIV-related large-cell lymphoma before versus after highly active antiretroviral therapy. J Clin Oncol 2005, 23:8477-8482.
66. Palmieri C., Triebel T., Large O., et al. AIDS-related non-Hodgkin's lymphoma in the first decade of highly active antiretroviral therapy. QJM 2006, 99:811-826.
67. Pakkala S., Chen Z., Rimland D., et al. Human immunodeficiency virus-associated lung cancer in the era of highly active antiretroviral therapy. Cancer 2012, 118:164-172.
68. D'Jaen G.A., Pantanowiitz L., Bower M., et al. Human immunodeficiency virus-associated primary lung cancer in the era of highly active antiretroviral therapy: a multi-institutional collaboration. Clin Lung Cancer 2010, 11:396-404.
69. Diaz P.T., King M.A., Pacht E.R., et al. Increased susceptibility to pulmonary emphysema among HIV-seropositive smokers. Ann Intern Med 2000, 132:369-372.
70. Petrache I., Diab K., Knox K.S., et al. HIV associated pulmonary emphysema: a review of the literature and inquiry into its mechanism. Thorax 2008, 63:463-469.
71. Morris A., George M.P., Crothers K., et al. HIV and chronic obstructive pulmonary disease. Is it worse and why?. Proc Am Thorac Soc 2011, 8:320-325.
72. George M.P., Kannass M., Huang L., et al. Respiratory symptoms and airway obstruction in HIV-infected subjects in the HAART era. PLoS One 2009, 4:e6328.
73. Cui O., Carruthers S., McIvor A., et al. Effect of smoking on lung function, respiratory symptoms and respiratory diseases amongst HIV-positive subjects: a cross-sectional study. AIDS Res Ther 2009, 7:6.
74. Gingo E.R., George M.P., Kessinger C., et al. Pulmonary function abnormalities in HIV-infected patients during the current antiretroviral therapy era. Am J Respir Crit Care Med 2010, 182:790-796.
75. Hsue P.Y., Deeks S.G., Farah H.H., et al. Role of HIV and human herpesvirus-8 infection in pulmonary arterial hypertension. AIDS 2008, 23:825-833.
76. Rich J.D., Shah S.J., Swamy R.S., et al. Inaccuracy of Doppler echocardiographic estimates of pulmonary artery pressures in patients with pulmonary hypertension: implications for clinical practice. Chest 2011, 139:988-993.